DMBT1 has a protective effect on allergic rhinitis

Area of Science:

• Immunology
• Allergy Research
• Molecular Biology

Background:

• Deleted in malignant brain tumors 1 (DMBT1) is a secreted scavenger receptor cysteine-rich (SRCR) protein found in nasal mucosal epithelial cells.
• Elevated DMBT1 levels were observed in the nasal mucosa of allergic rhinitis (AR) patients, suggesting a potential role in the condition.
• The precise mechanism of DMBT1's involvement in AR progression remained unclear prior to this study.

Purpose of the Study:

• To investigate the mechanism by which DMBT1 influences the progression of allergic rhinitis.
• To determine the therapeutic potential of DMBT1 in an AR mouse model.

Main Methods:

• Quantified DMBT1 levels in nasal lavage fluid and nasal mucosa of AR patients and control groups using ELISA and IHC.
• Administered recombinant DMBT1 (rDMBT1) intranasally to ovalbumin-sensitized mice.
• Assessed nasal symptoms, IL-4 and IL-5 levels in BAL fluid, and eosinophil infiltration in the nasal cavity.

Main Results:

• DMBT1 levels were significantly elevated in both AR patients and AR mice compared to controls.
• rDMBT1 treatment significantly reduced AR symptoms, including sneezing and rubbing, in mice.
• rDMBT1 administration inhibited eosinophil infiltration and decreased IL-4 and IL-5 production in the nasal cavity and BAL fluid.

Conclusions:

• Recombinant DMBT1 (rDMBT1) demonstrates a therapeutic effect by alleviating AR progression in a mouse model.
• rDMBT1 functions by inhibiting IL-4 and IL-5 production and reducing eosinophil infiltration in the nasal cavity.
• DMBT1 represents a promising therapeutic target for managing allergic rhinitis.